Biopharma Patients Pharmaceutical manufacturing 
European Pharmaceutical Review
SEPTEMBER 22, 2022
Moreover, pharmaceutical manufacturing poses a huge detriment to the state of the planet’s ecosystem. Active pharmaceutical ingredients (APIs) are particularly impact intensive, soaking up a large quantity of resources in terms of heat, energy and water when being produced.
Pharmaceutical Technology
SEPTEMBER 13, 2022
The company provides strategic assistance and regulatory support to biopharma firms across the lifecycle of the product. Additionally, it aids clients in introducing products to international markets and varied patient populations by delivering tech-driven services spanning from clinical development consultation to marketing authorisation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
DECEMBER 21, 2022
2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Green Chemistry in the Synthesis of Pharmaceuticals.
PM360
SEPTEMBER 30, 2024
In late 2023, Deloitte found that over half of 105 surveyed global biopharma leaders were committed to reducing environmental impact and advancing sustainability by minimizing water use, sourcing sustainable materials, and overhauling supply chains. REFERENCES 1.
Clarivate
MARCH 14, 2024
Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] Impending change affords an opportunity for innovation.
pharmaphorum
AUGUST 4, 2022
In particular, for the pharmaceutical industry, these talent shortages bring about a host of difficult challenges. This is due to the specialist nature of roles and the growth and diversification of biopharma, which requires an increasingly sophisticated and skilled workforce. Training and development.
Clarivate
AUGUST 20, 2024
1, 2024, following an IRA provision capping patients’ out-of-pocket costs at $35 per month. Payers may consider increased contracting with competitors of the ten selected drugs for preferred access while shifting them to a less-favorable tier, increasing patient out-of-pocket costs.
Expert insights. Personalized for you.
105 
Let's personalize your content